Amelie Harle Discusses Aprepitant for Cough in Lung Cancer

A Look Back at 2022 FDA Approvals in Oncology

Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo

Are Hearing Tests Necessary For Adult Cancer Survivors?

Patritumab Deruxtecan Elicits Durable Responses in Pretreated EGFR-Mutated NSCLC

Opinion: Tumor-Treating Fields Hold Promise in Metastatic Non–Small Cell Lung Cancer

Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups

A Look Back at 2022 FDA Approvals in Oncology

Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo

Are Hearing Tests Necessary For Adult Cancer Survivors?

Patritumab Deruxtecan Elicits Durable Responses in Pretreated EGFR-Mutated NSCLC

Opinion: Tumor-Treating Fields Hold Promise in Metastatic Non–Small Cell Lung Cancer

Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups

A Look Back at 2022 FDA Approvals in Oncology

Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo

Are Hearing Tests Necessary For Adult Cancer Survivors?

Patritumab Deruxtecan Elicits Durable Responses in Pretreated EGFR-Mutated NSCLC

Opinion: Tumor-Treating Fields Hold Promise in Metastatic Non–Small Cell Lung Cancer

Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups

Related Content

A Look Back at 2022 FDA Approvals in Oncology

Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease.

Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Are Hearing Tests Necessary For Adult Cancer Survivors?

The median progression-free survival was 25.5 months with osimertinib plus chemotherapy and 16.7 months with osimertinib alone.

Patritumab Deruxtecan Elicits Durable Responses in Pretreated EGFR-Mutated NSCLC

Podcast

In this episode of “The Vitals,” Christine Miaskowski, PhD, RN, discusses research showcasing that adult patients receiving either a platinum-based chemotherapy, taxane alone, or a combined regimen of platinum- and taxane-based treatment may be at risk of hearing loss.

Opinion: Tumor-Treating Fields Hold Promise in Metastatic Non–Small Cell Lung Cancer

Patrimumab deruxtecan garnered a 29.8% overall response rate in pretreated patients with EGFR-mutated non–small cell lung cancer.